Bioengineered EVs
Highly pure bioengineered EVs
Reference X130
Highly pure EVs, bioengineered with surface proteins
Our Bioengineered EVs are produced by human embryonic kidney (HEK) 293T stable cell line and purified according to in-EV purification process, combining Tangential Flow Filtration and chromatography.
Pure Bioengineered EVs are subjected to standardised quality controls showing the total protein content, the number of particles, the EV size distribution, the presence of internal EV markers and the absence of cell protein contaminants. CD81 surface marker presence is revealed by a direct ELISA on pure Bioengineered EVs.
Presence of the protein targeted to the EVs is also assessed.
Proteins of interest are targeted at the EV surface using Ciloa technology, without overexpression or modification of natural EV proteins.
Proteins of interest are targeted to the EVs thanks to the fusion with a peptide for specific sorting into EVs (Pilot Peptide, PP). This PP interacts with ESCRT machinery to sort proteins to the EVs.
By this way, several EVs have been developed, harboring :
human CCR-10 GPCR
human CCR-7 GPCR
human ALK-2 receptor
human MISRII receptor
human ALK-4 receptor
Schematic representation of Ciloa technology to sort proteins to the EVs.
